TMS as a Treatment for Apathy in Alzheimer's Disease
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Charlestown, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 3 people enrolled
- Started
- 2 May 2024
- Ended
- 28 Oct 2024
- Type of study
- Interventional, 3 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Intermittent Theta Burst Stimulation (iTBS)
- Record updated
- 15 May 2025
- Why it stopped
- Unable to fulfill recruitment goals
Who can take part
- Age
- 50 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age 50-80
- A clinical diagnosis of Alzheimer's disease, including atypical variants of this (e.g., the behavioral/dysexecutive variant, the logopenic Primary Progressive Aphasia variant, Posterior Cortical Atrophy variant, etc.)
- Clinical Dementia Rating of 0.5 or mild 1.0 (MMSE equal to or greater than 22)
- Patients must be accompanied to visits by a study partner/informant (usually a spouse or adult child)
- Prominent symptoms of apathy reported by their primary caregiver/informant and verified with a score of greater than or equal to 45 on the informant version of the Apathy Evaluation Scale (AES-I)
Who cannot take part
- Any contraindication to receiving TMS (e.g., a history of seizures, cochlear implants)
- Concurrent use of tobacco or illicit drugs, particularly those affecting dopamine transmission. Patients will be asked to refrain from using caffeine the morning of experimental procedures
- Clinical dependence on psychotropic medications believed to affect dopamine binding (e.g., certain antidepressants or especially neuroleptics). If the patient is clinically able to temporarily wean off of these, they will be included after the medication has been discontinued and fully eliminated (e.g., a duration of five half-lives). Subjects will also be excluded if they have a history of long-term use of these agents (particularly neuroleptics)
- Any contraindication to MR-PET scanning (e.g., pacemakers, implanted metal, aneurysm clips, etc.)
- Involvement in any PET studies within 12 months
Where in United States
- Martinos Center for Biomedical Imaging/Massachusetts General HospitalCharlestown, United States
About the trial
What the trial wants to find out
This proposal will demonstrate that non-invasive brain stimulation is able to modulate cortico-striatal circuits in neurodegenerative patients with apathy, and that doing so results in circuit-specific increases in FC and DA availability. These circuit changes will be accompanied by changes in specific behavioral dimensions of apathy. This work will lead to larger studies which develop personalized, circuit-specific neuromodulation strategies for AD patients suffering from this intractable neuropsychiatric symptom.
The 3 groups in the trial
- Dorsal circuit (DLPFC) stimulationTreatment being tested
This arm will involve stimulation of the dorsal apathy-relevant circuit. Specifically, a target will be individually selected based on resting-state functional connectivity with a given subject's dorsal striatum.
Treatment: Intermittent Theta Burst Stimulation (iTBS)
- Ventral circuit (vmPFC) stimulationTreatment being tested
This arm will involve stimulation of the ventral apathy-relevant circuit. Specifically, a target will be individually selected based on resting-state functional connectivity with a given subject's ventral striatum.
Treatment: Intermittent Theta Burst Stimulation (iTBS)
- Sham stimulationSham treatment, for comparison
This arm will involve sham stimulation to a prefrontal target.
Treatment: Intermittent Theta Burst Stimulation (iTBS)
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Circuit-specific Neuromodulation for the Treatment of Apathy in Alzheimer's Disease
- Record updated
- 15 May 2025